Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,149 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Global prevalence and major risk factors of diabetic retinopathy.
Yau JW, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, Chen SJ, Dekker JM, Fletcher A, Grauslund J, Haffner S, Hamman RF, Ikram MK, Kayama T, Klein BE, Klein R, Krishnaiah S, Mayurasakorn K, O'Hare JP, Orchard TJ, Porta M, Rema M, Roy MS, Sharma T, Shaw J, Taylor H, Tielsch JM, Varma R, Wang JJ, Wang N, West S, Xu L, Yasuda M, Zhang X, Mitchell P, Wong TY; Meta-Analysis for Eye Disease (META-EYE) Study Group. Yau JW, et al. Among authors: porta m. Diabetes Care. 2012 Mar;35(3):556-64. doi: 10.2337/dc11-1909. Epub 2012 Feb 1. Diabetes Care. 2012. PMID: 22301125 Free PMC article. Review.
Variation in SLC19A3 and Protection From Microvascular Damage in Type 1 Diabetes.
Porta M, Toppila I, Sandholm N, Hosseini SM, Forsblom C, Hietala K, Borio L, Harjutsalo V, Klein BE, Klein R, Paterson AD; DCCT/EDIC Research Group; Groop PH; FinnDiane Study Group. Porta M, et al. Diabetes. 2016 Apr;65(4):1022-30. doi: 10.2337/db15-1247. Epub 2015 Dec 30. Diabetes. 2016. PMID: 26718501 Free PMC article.
Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials.
Chaturvedi N, Porta M, Klein R, Orchard T, Fuller J, Parving HH, Bilous R, Sjølie AK; DIRECT Programme Study Group. Chaturvedi N, et al. Among authors: porta m. Lancet. 2008 Oct 18;372(9647):1394-402. doi: 10.1016/S0140-6736(08)61412-9. Epub 2008 Sep 25. Lancet. 2008. PMID: 18823656 Clinical Trial.
Effects of Topically Administered Neuroprotective Drugs in Early Stages of Diabetic Retinopathy: Results of the EUROCONDOR Clinical Trial.
Simó R, Hernández C, Porta M, Bandello F, Grauslund J, Harding SP, Aldington SJ, Egan C, Frydkjaer-Olsen U, García-Arumí J, Gibson J, Lang GE, Lattanzio R, Massin P, Midena E, Ponsati B, Ribeiro L, Scanlon P, Lobo C, Costa MÂ, Cunha-Vaz J; European Consortium for the Early Treatment of Diabetic Retinopathy (EUROCONDOR). Simó R, et al. Among authors: porta m. Diabetes. 2019 Feb;68(2):457-463. doi: 10.2337/db18-0682. Epub 2018 Nov 2. Diabetes. 2019. PMID: 30389750 Clinical Trial.
Angiotensin receptor blockade not related to history of dry eye symptoms and treatment in The Diabetic Retinopathy Candesartan Trials (DIRECT).
Moss SE, Klein R, Sjølie AK, Chaturvedi N, Malm AR, Fuller JH, Porta M; DIRECT Programme Study Group. Moss SE, et al. Among authors: porta m. Acta Ophthalmol. 2011 Sep;89(6):e535-6. doi: 10.1111/j.1755-3768.2010.01992.x. Epub 2010 Aug 31. Acta Ophthalmol. 2011. PMID: 20809912 Free article. Clinical Trial. No abstract available.
1,149 results